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Cryptococcosis is an invasive fungal infection
most often caused by the encapsulated yeasts
Cryptococcus neoformans and Cryptococcus gattii.
C neoformans is the major pathogenic member of
the genus, thought to account for approximately 80%
of isolates worldwide, and is found in pigeon
droppings, soil, and rotting vegetation.1 The inci-
dence in the United States is approximately 5 cases
per 100,000.2 However, the global burden is much
more significant, with more than 1 million new cases
and more than 600,000 deaths a year.3
Most patients with cryptococcosis are immuno-
compromised because of HIV infection, immuno-
suppressive therapy, or malignancy. Although
cryptococcal infections begin in the lungs via inha-
lation of the basidiospore, the classical clinical
manifestation is meningoencephalitis. Nonmenin-
geal, nonpulmonary symptoms are less common
and generally reflect disseminated disease.
Cutaneous manifestations are seen in approximately
15% of patients with systemic cryptococcosis and can
have a variety of presentations, including papules,
plaques, and ulcers.4 Here we present an uncommon
case of cutaneous cryptococcosis presenting as
cellulitis in a heart transplant recipient.
CASE REPORT
A 45-year-old African-American man, 10 years
posteheart transplant for end-stage nonischemic
cardiomyopathy, presented to our hospital with athe Division of Infectious Diseases, Department of Medicineb
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swelling of his right thigh. His immunosuppressive
regimen included tacrolimus, 1 mg twice daily,
prednisone, 10 mg daily, and mycophenolate mofe-
til, 500 mg twice daily. Upon arrival at our hospital,
the patient was afebrile, and vital signs were within
normal limits. On physical examination he had a
large erythematous patch on his right medial thigh
that extended down his medial leg to his ankle. His
preliminary laboratory results showed a white blood
cell count of 14.6 3 103/uL, with a neutrophilic
predominance of 93%. Blood cultures were sent
before starting the patient on cefepime and vanco-
mycin for presumed bacterial cellulitis.
Over the next few days, the patient’s symptoms
improved but did not resolve. The redness regressed,
leaving behind 2 distinct, indurated, red-brown
patches on his medial thigh and medial distal calf
(Fig 1, A and B). The dermatology department was
consulted and performed biopsies of both sites.
Histopathologic evaluation found granulomatous
inflammation throughout the mid-to-reticular dermis
extending in some areas to the superficial subcu-
taneous fat, with scattered budding yeast (Fig 2, A
through C ). Subsequent workup included a lumbar
puncture, which found an elevated openingJAAD Case Reports 2016;2:403-5.
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Fig 1. Cryptococcal cellulitis. A, A 45-year-old man with a dull, red-brown patch with dermal
induration on the rightmedial thigh.B, A second similar but smaller patch on themedial right leg.
Fig 2. A, Skin biopsy from the right medial thigh shows extensive granulomatous inflammation
and scattered encapsulated and budding yeast. B, Higher-power image shows numerous round
fungi with thick, gelatinous capsules. C, Methenamine silver stain shows abundant budding
yeast. (A, and B, Hematoxylin-eosin stain; C, methenamine silver stain; original magnifications:
A, 310; B, and C, 340.)
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antigen. Cerebrospinal fluid and blood cultures were
normal. The patient was started on a 2-week course
of liposomal amphotericin B and 5-flucytosine with
improvement in his cellulitis and was discharged on
fluconazole for maintenance therapy.
DISCUSSION
Cryptococcal infection in immunocompetent adults
is most commonly asymptomatic but rarely can lead to
a focal pneumonitis.5 Immunocompromised patients,in contrast, have a much higher risk of having
disseminated disease that can affect any organ
system in the body. Historically, HIV-infected pa-
tients had the greatest risk for disseminated crypto-
coccosis. However, with improving highly active
antiretroviral therapy, organ transplant patients are
emerging as a prominent group affected by this
opportunistic infection. The mean incidence of C
neoformans infection in organ transplant recipients
is 3 per 100 patients, with a mortality rate of
approximately 40%.6
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rare overall but may be more common in organ
transplant recipients.7 One prominent theory for this
occurrence is that tacrolimus is toxic to C neofor-
mans, especially in the central nervous system (CNS)
where it effectively inhibits calcineurin at 378C.8 This
inhibition likely breaks down at cooler sites of the
body, such as the skin, which may allow the organ-
ism to thrive. This theory is supported by studies that
found that cutaneous manifestations of disseminated
cryptococcosis are more common than CNS mani-
festations in organ transplant recipients on tacroli-
mus therapy—67% present with cutaneous
manifestations versus 17% with CNS manifestations.6
The classical cutaneous manifestation of crypto-
coccosis is umbilicated papules, most commonly
seen in AIDS patients, but it can also present as
acneiform papules, plaques, and ulcers.4 In our
patient, the persistence of erythema despite appro-
priate antibiotic treatment for bacterial cellulitis, the
red-brown color, and the indurated feel of the skin
were all clues to an atypical infectious process.
Interestingly, a brown hue may be an important
clue to cryptococcosis. C neoformans possesses a
virulence factor, phenol oxidase, which catalyzes
one step in the conversion of phenolic compounds
(namely, catacholamines such as dopamine) into
melanin. Melanin accumulates in the tissue and cell
wall of C neoformans, where it acts as an antioxidant
and protects against attack by immune modulator
cells.9 This finding likely explains the brown color-
ation of the skin and perhaps also the predilection of
Cryptococcus for the CNS, where there are high
concentrations of dopamine.
Cutaneous cryptococcosis in immunocompro-
mised patients should be viewed as a sign of dissem-
inated disease and should prompt further evaluation.
Early diagnosis and treatment are critical, as mortality
rates are alarmingly high. Treatment of disseminatedcryptococcosis in transplant patients is divided into 3
phases. Generally, the treatment of choice is liposomal
amphotericin B (3e4 mg/kg/d) with or without
flucytosine (50e150 mg/kg/d) for 2 weeks of induc-
tion therapy, followed by fluconazole, 400 mg/d for
8 weeks of consolidation therapy, and fluconazole,
200 mg/d for 6 months of maintenance therapy.10REFERENCES
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